Bristol-Myers Squibb Co (NYSE:BMY) Stake Decreased by Boston Private Wealth LLC

Boston Private Wealth LLC cut its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 167,758 shares of the biopharmaceutical company’s stock after selling 1,948 shares during the period. Boston Private Wealth LLC’s holdings in Bristol-Myers Squibb were worth $10,693,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Blue Chip Partners Inc. raised its holdings in shares of Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 15 shares during the last quarter. Jackson Grant Investment Advisers Inc. raised its holdings in shares of Bristol-Myers Squibb by 0.4% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 15 shares during the last quarter. Chilton Investment Co. LLC raised its holdings in shares of Bristol-Myers Squibb by 0.5% during the second quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after purchasing an additional 26 shares during the last quarter. Keel Point LLC raised its holdings in shares of Bristol-Myers Squibb by 0.6% during the second quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 39 shares during the last quarter. Finally, Hudock Capital Group LLC raised its holdings in shares of Bristol-Myers Squibb by 0.4% during the second quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 49 shares during the last quarter. Hedge funds and other institutional investors own 69.56% of the company’s stock.

Bristol-Myers Squibb Co (BMY) opened at $63.16 on Tuesday. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The firm has a market cap of $103,370.00, a P/E ratio of 107.05, a P/E/G ratio of 1.94 and a beta of 1.08. Bristol-Myers Squibb Co has a twelve month low of $51.56 and a twelve month high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping the consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 33.68%. The company had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same quarter in the previous year, the business posted $0.63 EPS. The firm’s revenue was up 3.9% on a year-over-year basis. research analysts expect that Bristol-Myers Squibb Co will post 3.22 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Friday, January 5th were given a $0.40 dividend. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Thursday, January 4th. This represents a $1.60 annualized dividend and a yield of 2.53%. Bristol-Myers Squibb’s dividend payout ratio is 271.19%.

Several analysts recently commented on the stock. Vetr lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target on the stock. in a research report on Thursday, February 8th. BMO Capital Markets dropped their price target on shares of Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 6th. Leerink Swann lifted their target price on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a research report on Tuesday, February 6th. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Monday, January 29th. Finally, Credit Suisse Group set a $62.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, January 22nd. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $65.58.

In related news, Director Theodore R. Samuels II purchased 4,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was acquired at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the acquisition, the director now directly owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the transaction, the executive vice president now owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/13/bristol-myers-squibb-co-bmy-shares-sold-by-boston-private-wealth-llc.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply